3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
8
Terminated
4
Recruiting
2
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Tumor-Agnostic
1
Conditions
Thyroid Neoplasms
2
Neoplasms
2
Melanoma
2
Xanthogranuloma, Juvenile
1
Wilms Tumor
1
Thyroid Carcinoma, Anaplastic
1
Thyroid Cancer, Papillary
1
Skin Neoplasms
1
Sarcoma, Ewing
1
Sarcoma
1
Rhabdomyosarcoma
1
Rhabdoid Tumor
1
Osteosarcoma
1
Neuroectodermal Tumors, Primitive, Peripheral
1
Neuroblastoma
1
Neoplasm Metastasis
1
Medulloblastoma
1
Lymphoma, Non-Hodgkin
1
Leukemia, Hairy Cell
1
Leukemia
1
Histiocytosis, Langerhans-Cell
1
Histiocytic Sarcoma
1
Hepatoblastoma
1
Glioma
1
Ependymoma
1
Craniopharyngioma
1
Central Nervous System Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
pembrolizumab
34
Specimen Handling
18
Paclitaxel
16
Magnetic Resonance Spectroscopy
15
Carboplatin
14
Biopsy
14
Nivolumab
13
Ipilimumab
12
Gemcitabine
10
Irinotecan
9
Radiosurgery
8
atezolizumab
7
abemaciclib
7
Radiation
7
Pemetrexed
7
Cisplatin
7
Capecitabine
7
130-nm albumin-bound paclitaxel
7
trastuzumab deruxtecan
6
olaparib
6
durvalumab
6
avelumab
6
Docetaxel
6
osimertinib
5
adagrasib
5
Trastuzumab
5
Fulvestrant
5
Cetuximab
5
Albumin-Bound Paclitaxel
5
palbociclib
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Active not recruiting
×
Neoplasm Metastasis
×
Vemurafenib
×
Clear all
NCT02304809
2025-08-01
AcSé
UNICANCER
Phase 2
Active not recruiting
216 enrolled